Evidence map›Paper›PMID 41531611›Full record

ArticleCureus2025

Substance Use and Cardiac Implantable Electronic Devices: A Single Institution Analysis of Re-Hospitalization, Follow-Up Rate, and Complications to Predict Patient Outcomes.

Abby Stoecker, Paul Kang, Michael D White

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abby StoeckerCollege of Medicine, Creighton University School of Medicine, Phoenix, USA.
Paul KangSchool of Medicine, Creighton University School of Medicine, Phoenix, USA.
Michael D WhiteCardiology, Creighton University School of Medicine, Omaha, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Illicit drug use is a prevalent issue in Phoenix, Arizona, and is associated with various health concerns, including disrupting the conduction system of the heart. Cardiac implantable electronic devices (CIEDs), such as pacemakers and cardioverter-defibrillators, are common treatment options for conduction abnormalities. However, there is ongoing debate regarding the implantation of CIEDs in patients reporting active substance use, hypothesized to stem from provider concerns around lead endocarditis and poor follow-up adherence. Currently, information in the literature regarding outcomes of CIED patients with active substance use is lacking. This study aims to bridge this gap through evaluating differences in rehospitalization, follow-up, and CIED-related complications among patients with and without current substance use. Methods Patient records between January 2020 and December 2024 of those who received care at Valleywise Health in Phoenix, Arizona, were reviewed. All patients with complete records who had a CIED were included in the study. Covariates included patient demographics, substance use status, comorbidities, problems with CIED (infection, malfunction, adjustment/reprogramming), number of encounters, rehospitalization rates at 30 days, 90 days, and one year, and office follow-up rates. Continuous variables were compared between substance use statuses using the independent T-test or the Wilcoxon Rank Sum. Categorical variables were compared using the chi-squared analysis. Odds ratios (95% CI) were calculated using logistic regression to assess the association between substance use status, rehospitalization, and office follow-up while adjusting for potential confounding variables. Logistic regression modeling was repeated following a propensity score match to create comparable cohorts between patients with and without current substance use. Results A total of 2,522 patients were included in the study, with 90.4% reporting no current substance use and 9.64% reporting current substance use. There were no differences in 30-day, 90-day, and one-year rehospitalizations between patients with current substance use and patients with no substance use. There was also no difference in follow-up rates between these groups. In the unmatched analysis, Hispanic/Latino patients were less likely to have 30-day, 90-day, and one-year rehospitalizations compared to non-Hispanic/Latino patients. In the matched analysis, this was no longer significant. Additionally, in the unmatched analysis, patients reporting no substance use had more device malfunctions, adjustments, and infections compared to patients with current substance use. This difference was not seen following the propensity score match. Finally, patients who were unhoused were 23-fold (unmatched analysis) and 33-fold (matched analysis) more likely to have office follow-ups compared to housed patients. Conclusion This study demonstrated a lack of statistical difference in rehospitalizations and follow-ups between patients with CIEDs with and without substance use. This study also demonstrated that patients with CIEDs and current substance use were not at an increased risk for device infections or malfunctions compared to patients without current substance use. Further studies are necessary with larger populations to validate these conclusions.

Indexed as

cardiac implantable electronic device (cied)implantable cardioverter defibrillatorlead endocarditispacemakersubstance use

Identifiers

PMID41531611
PMCPMC12794526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.